1-(Benzothiazol-2-Yl)-4Aminomethylpiperidine | 137309-83-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 1-(Benzothiazol-2-Yl)-4Aminomethylpiperidine
• 英文别名: {[1-(1,3-Benzothiazol-2-yl)piperidin-4-yl]methyl}amine；[1-(1,3-benzothiazol-2-yl)piperidin-4-yl]methanamine
• CAS: 137309-83-2
• 化学式: C₁₃H₁₇N₃S
• 分子量: 247.364
• InChiKey: HCJHYIPKWYXQCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  70.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(苯并噻唑-2-基)-4-氨基甲基哌啶盐酸盐 以 sodium hydroxide 为溶剂， 生成 1-(Benzothiazol-2-Yl)-4Aminomethylpiperidine
  参考文献：
  名称：

  Aminomethylpiperidine compounds

  摘要：

  本发明涉及一般式(I)的化合物。##STR1## 其中X代表硫或氧原子，或取代或未取代的氨基团；R代表氢原子或A、B、C、D、E、F或G中的任何一个基团；R'代表氢原子、烷基团或A、B、C、D、E或F中的任何一个基团，当R=G时，R'=H；或R和R'与它们所连接的氮原子形成一个可选的取代哌嗪环。药物。

  公开号：

  US05229399A1

文献信息

• [EN] 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DERIVES AMIDES DE L'ACIDE CARBOXYLIQUE DE 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE 3 ET COMPOSES ASSOCIES EN TANT QU'ANTAGONISTES DE RECEPTEUR DE B1 DE LA BRADYKININE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：ELAN PHARM INC

  公开号：WO2004098589A1

  公开（公告）日：2004-11-18

  Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  公开的是化合物I和II的结构式，它们是激肽酶B1受体拮抗剂，适用于治疗哺乳动物中由激肽酶B1受体介导的疾病，或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力，并且预计还将表现出延长作用的特性。
• New aminomethylpiperidine compounds
  申请人：Adir et Compagnie

  公开号：US05192775A1

  公开（公告）日：1993-03-09

  The invention relates to compounds of general formula (I). ##STR1## in which X represents an atom of sulfur or oxygen, or a substituted or unsubstituted amino group; R represents a hydrogen atom or any one of groups A, B, C, D, E, F, or G; R' represents a hydrogen atom, an alkyl group or any one of groups A, B, C, D, E or F, with R'=H when R=G; or R and R' form, with the nitrogen atom to which they are attached, an optionally substituted piperazine ring. Medicaments.

  本发明涉及一般式（I）的化合物。 ##STR1## 其中X代表硫或氧原子，或取代或未取代的氨基团；R代表氢原子或A、B、C、D、E、F或G中的任何一个；R'代表氢原子、烷基团或A、B、C、D、E或F中的任何一个，当R=G时，R'=H；或者R和R'与它们所连接的氮原子形成一个可选取代的哌嗪环。药物。
• Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
  申请人：Tung S. Jay

  公开号：US20050020659A1

  公开（公告）日：2005-01-27

  Disclosed are compounds that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  本发明公开了一种布雷肯肽B1受体拮抗剂化合物，可用于治疗哺乳动物中由布雷肯肽B1受体介导的疾病或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力，并且预计也会表现出增强的作用持续时间。
• 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
  申请人：Tung S. Jay

  公开号：US20060281733A1

  公开（公告）日：2006-12-14

  Disclosed are compounds of formula I and II that are bradykinin B 1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B 1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  本发明公开了式I和式II的化合物，它们是缓激肽B1受体拮抗剂，可用于治疗哺乳动物中由缓激肽B1受体介导的疾病，或缓解与疾病条件相关的不良症状。其中某些化合物表现出增强的效力，预计也会表现出增强的持续时间。
• Substituted N-[(4-piperidinyl)alkyl] bicyclic condensed ozazol- and thiazolamines
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0199400A2

  公开（公告）日：1986-10-29

  Novel substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol-and thiazolamines of formula wherein L is a radical or the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof, which compounds have anti-depressive, anti-Parkinson and enterokinetic activity; pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.

  式中的新型取代 N-[(4-哌啶基)烷基]双环缩合噁唑和噻唑胺 其中 L 是自由基 或 药学上可接受的酸加成盐及其可能的立体化学异构形式，这些化合物具有抗抑郁、抗帕金森和肠动力活性；含有这些化合物作为活性成分的药物组合物以及制备所述化合物和药物组合物的方法。